Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
Want to see CRBP full AI Analyst Report?
Top Page
Corbus Pharmaceuticals
(NASDAQ:CRBP)
Select Model
Select Model
Rating:56Neutral
Price Target:
$10.50
▲(3.55% Upside)
Action:ReiteratedDate:04/17/26
The score is held back primarily by weak financial performance (pre-revenue, rising losses and cash burn), partially offset by an improved, low-debt balance sheet. Technicals are moderately constructive with price above key short/mid-term averages and positive MACD. Pipeline/regulatory milestones and extended cash runway support sentiment, but valuation signals are limited due to negative earnings and no stated dividend yield.
Positive Factors
Improved balance sheet
Positive equity and minimal debt give Corbus durable financial flexibility to fund multi-year clinical programs without immediate refinancing pressure. Low leverage reduces bankruptcy risk, supports partnering or selective M&A, and preserves optionality while trials advance toward registrational stages.
Negative Factors
High cash burn
Sustained, rising operating cash burn increases the probability of future dilutive financings and constrains the firm's ability to advance multiple programs simultaneously. Even with current runway, persistent negative OCF erodes flexibility and heightens execution risk if clinical timelines slip or costs rise further.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved balance sheet
Positive equity and minimal debt give Corbus durable financial flexibility to fund multi-year clinical programs without immediate refinancing pressure. Low leverage reduces bankruptcy risk, supports partnering or selective M&A, and preserves optionality while trials advance toward registrational stages.
Read all positive factors
Corbus Pharmaceuticals (CRBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$177.36M
Dividend YieldN/A
Average Volume (3M)503.64K
Price to Earnings (P/E)―
Beta (1Y)1.61
Revenue GrowthN/A
EPS Growth-17.43%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.25
Shares Outstanding17,736,464
10 Day Avg. Volume744,820
30 Day Avg. Volume503,638
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.71
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$39.43Price Target Upside288.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.59
Revenue Forecast (FY)$2.00M
Corbus Pharmaceuticals Business Overview & Revenue Model
Company Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor ...
How the Company Makes Money
Corbus primarily generates revenue from collaboration and licensing arrangements rather than from marketed product sales. Historically, this has included recognizing collaboration-related revenue (e.g., upfront payments and/or other amounts associ...
Corbus Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 881.71K |
| Gross Profit | -233.00K | -600.00K | 0.00 | -1.49M | -757.53K |
| EBITDA | -85.08M | -37.74M | -40.10M | -38.73M | -54.35M |
| Net Income | -78.54M | -40.21M | -44.60M | -55.83M | -45.55M |
Balance Sheet | |||||
| Total Assets | 168.19M | 155.88M | 28.27M | 66.31M | 107.73M |
| Cash, Cash Equivalents and Short-Term Investments | 163.94M | 149.06M | 20.91M | 59.20M | 97.65M |
| Total Debt | 1.63M | 3.24M | 20.89M | 25.09M | 26.59M |
| Total Liabilities | 20.69M | 13.45M | 35.18M | 33.32M | 38.62M |
| Stockholders Equity | 147.50M | 142.43M | -6.91M | 32.99M | 69.11M |
Cash Flow | |||||
| Free Cash Flow | -64.50M | -41.79M | -36.10M | -37.56M | -48.24M |
| Operating Cash Flow | -64.49M | -41.79M | -36.10M | -37.54M | -48.18M |
| Investing Cash Flow | -1.64M | -121.31M | 35.64M | 30.07M | -73.42M |
| Financing Cash Flow | 77.43M | 166.58M | -2.82M | -533.62K | 60.82M |
Corbus Pharmaceuticals Technical Analysis
Positive
10.14
Price Trends
8.77
Positive
8.97
Positive
10.11
Positive
Market Momentum
0.37
Negative
58.34
Neutral
45.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBP, the sentiment is Positive. The current price of 10.14 is above the 20-day moving average (MA) of 9.44, above the 50-day MA of 8.77, and above the 200-day MA of 10.11, indicating a bullish trend. The MACD of 0.37 indicates Negative momentum. The RSI at 58.34 is Neutral, neither overbought nor oversold. The STOCH value of 45.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRBP.
Corbus Pharmaceuticals Risk Analysis
Corbus Pharmaceuticals disclosed 51 risk factors in its most recent earnings report. Corbus Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Corbus Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $177.36M | -1.38 | -65.76% | ― | ― | -17.43% | |
54 Neutral | $142.43M | 4.86 | -209.00% | ― | ― | 40.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $60.88M | -1.00 | -71.28% | ― | -10.03% | 11.06% | |
46 Neutral | $49.43M | -2.19 | -65.56% | ― | ― | -9.42% |
* Healthcare Sector Average
CRBP
Corbus Pharmaceuticals
10.59
4.29
68.10%
ATOS
Atossa Therapeutics
5.83
-3.52
-37.62%
BMEA
Biomea Fusion
1.93
0.21
12.21%
TCRX
TScan Therapeutics
1.08
-0.45
-29.41%
Corbus Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board Changes
Corbus Pharmaceuticals Updates Executive Employment Agreements and Protections
Positive
Apr 16, 2026
On April 15, 2026, Corbus Pharmaceuticals entered into amended and restated employment agreements with Chief Executive Officer Yuval Cohen and Chief Financial Officer Sean Moran, setting new two-year terms through April 15, 2028 with increased cla...
Business Operations and StrategyProduct-Related Announcements
Corbus Advances CANYON-1 Phase 1b Obesity Trial Milestone
Positive
Apr 14, 2026
On April 14, 2026, Corbus Pharmaceuticals announced that the last patient had been enrolled and completed the first clinical visit in its CANYON-1 Phase 1b trial of CRB-913 for obesity, keeping the 16-week dose-finding study on schedule for comple...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Corbus Aligns With FDA on CRB-701 Registrational Path
Positive
Apr 7, 2026
On April 7, 2026, Corbus Pharmaceuticals announced it had reached broad alignment with the U.S. Food and Drug Administration on the registration path for its Nectin-4 targeting antibody-drug conjugate CRB-701 in second-line head and neck squamous ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Corbus Pharmaceuticals Highlights 2025 Results and Pipeline Progress
Positive
Mar 9, 2026
On March 9, 2026, Corbus Pharmaceuticals reported fourth-quarter and full-year 2025 results, highlighting strong clinical progress across its pipeline and a bolstered balance sheet. In oncology, Q4 2025 Phase 1/2 data for CRB-701 in head and neck ...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Corbus Highlights Diversified Oncology and Metabolic Pipeline Outlook
Positive
Feb 25, 2026
Corbus Pharmaceuticals presented an updated corporate overview dated February 25, 2026, highlighting a diversified pipeline led by CRB-701, a next-generation Nectin-4–targeting ADC designed for longer half-life, reduced free MMAE exposure, f...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.